Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Mar 15:2018:9506979.
doi: 10.1155/2018/9506979. eCollection 2018.

The International Prognostic Index for Patients with Chronic Lymphocytic Leukemia Has the Higher Value in Predicting Overall Outcome Compared with the Barcelona-Brno Biomarkers Only Prognostic Model and the MD Anderson Cancer Center Prognostic Index

Carolina Muñoz-Novas  1 , María Poza-Santaella  2 , Isabel González-Gascón Y Marín  1   2 , María Hernández-Sánchez  3 , Ana-Eugenia Rodríguez-Vicente  3 , María-Stefania Infante  1 , Cecilia Heras  1 , María-Ángeles Foncillas  1 , Karen Marín  1 , Jesús-María Hernández-Rivas  3 , José-Ángel Hernández  1   2
Affiliations

The International Prognostic Index for Patients with Chronic Lymphocytic Leukemia Has the Higher Value in Predicting Overall Outcome Compared with the Barcelona-Brno Biomarkers Only Prognostic Model and the MD Anderson Cancer Center Prognostic Index

Carolina Muñoz-Novas et al. Biomed Res Int. .

Abstract

In recent years, new prognostic indexes (PIs) for chronic lymphocytic leukemia (CLL), which include clinical, biological, and genetic variables, have been validated, highlighting the MD Anderson Cancer Center prognostic index (MDACC PI), the CLL-international prognostic index (CLL-IPI), and the Barcelona-Brno biomarkers only prognostic model. The aim of this study is to compare the utility of these PIs in a cohort of Spanish patients. A retrospective analysis of 696 unselected CLL patients newly diagnosed and previously untreated from different Spanish institutions was performed. The MDACC PI, the CLL-IPI, and the biomarkers only PI were applied to these patients, and a comparison of the three PIs was performed. With a median follow-up time of 46 months, 394 patients were alive and 187 had received treatment. The median overall survival (OS) was 173 months and the median time to first therapy (TTFT) was 32 months. Significant differences were obtained in OS and TTFT for all subgroups when applying these PIs, with the CLL-IPI being the one with the higher c-index (0.676 for OS and 0.757 for TTFT). The three PIs were able to discriminate patients in different prognostic subgroups. In our cohort, the CLL-IPI showed higher power in predicting TTFT and OS.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Survival analysis for patients stratified according to the MDACC score. (a) Overall survival analysis. (b) Time to first therapy analysis.
Figure 2
Figure 2
Survival analysis for patients stratified according to the CLL-IPI score. (a) Overall survival analysis. (b) Time to first therapy analysis.
Figure 3
Figure 3
Survival analysis for patients stratified according to the Barcelona-Brno biomarkers only prognostic model. (a) Overall survival analysis. (b) Time to first therapy analysis.
See this image and copyright information in PMC

References

    1. Baliakas P., Mattsson M., Stamatopoulos K., Rosenquist R. Prognostic indices in chronic lymphocytic leukaemia: where do we stand how do we proceed? Journal of Internal Medicine. 2016;279(4):347–357. doi: 10.1111/joim.12455. - DOI - PubMed
    1. Kipps T. J., Stevenson F. K., Wu C. J., et al. Chronic lymphocytic leukaemia. Nature Reviews Disease Primers. 2017;3, article 17008 doi: 10.1038/nrdp.2017.8. - DOI - PubMed
    1. Dighiero G. CLL biology and prognosis. Hematology/The Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 2005;2005(1):278–284. doi: 10.1182/asheducation-2005.1.278. - DOI - PubMed
    1. Hernández J. Á., González M., Hernández J. M. Chronic lymphocytic leukemia. Medicina Clínica. 2010;135(4):172–178. doi: 10.1016/j.medcli.2009.10.016. - DOI - PubMed
    1. Rai K. R., Sawitsky A., Cronkite E. P., Chanana A. D., Levy R. N., Pasternack B. S. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46(2):219–234. - PubMed

Substances

LinkOut - more resources